{"brief_title": "A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS and Advanced ARC Patients With Anemia", "brief_summary": "To determine the safety and efficacy of r-HuEPO administration to patients with AIDS or advanced AIDS related complex (ARC) and anemia secondary to their disease.", "condition": ["HIV Infections", "Cytopenias"], "intervention_type": ["Drug"], "intervention_name": ["Epoetin alfa"], "criteria": "Exclusion Criteria Co-existing Condition: Patients with the following are excluded: - History of any primary hematologic disease. - HIV disease related dementia. - Uncontrolled hypertension (diastolic blood pressure > 100 mmHg). - Presence of concomitant iron deficiency. - Anemia attributable to factors other than HIV disease or zidovudine (AZT) therapy. - Acute opportunistic infection. - History of seizures. - Clinically significant disease / dysfunction of the pulmonary, cardiovascular, endocrine, neurologic, gastrointestinal, or genitourinary systems not attributable to underlying HIV disease. Concurrent Medication: Excluded: - Zidovudine (AZT) therapy during the double-blind phase of study. Patients with the following are excluded: - History of any primary hematologic disease. - Clinically significant disease / dysfunction of the pulmonary, cardiovascular, endocrine, neurologic, gastrointestinal, or genitourinary systems not attributable to underlying HIV disease. - HIV disease related dementia. - Uncontrolled hypertension (diastolic blood pressure > 100 mmHg). - Presence of concomitant iron deficiency. Prior Medication: Excluded within 30 days of study entry: - Experimental drug or experimental device. - Cytotoxic chemotherapy. - Excluded within 2 months of study entry: - Androgen therapy. - Zidovudine (AZT) therapy and during the double-blind phase. Clinical diagnosis with AIDS or AIDS related complex (ARC) and related anemia. - Clinical diagnosis of AIDS or ARC. - Clinically stable for 1 month preceding study entry. - Patients should preferably be transfusion dependent. Substance abuse.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "75 Years", "healthy_volunteers": "No", "keyword": "Zidovudine", "mesh_term": ["Anemia", "HIV Infections", "Epoetin Alfa"], "id": "NCT00002042"}